Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Evercore ISI

Evercore ISI initiated coverage on shares of Evommune (NYSE:EVMN) in a report released on Monday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $40.00 price target on the stock. Evercore ISI’s price target indicates a potential upside of 85.70% from the company’s current price.

Several other equities analysts have also weighed in on the company. Leerink Partnrs upgraded Evommune to a “strong-buy” rating in a report on Monday. Wall Street Zen raised Evommune to a “hold” rating in a research note on Thursday, November 20th. Cantor Fitzgerald started coverage on Evommune in a research report on Monday. They set an “overweight” rating for the company. Leerink Partners began coverage on Evommune in a report on Monday. They set an “outperform” rating and a $42.00 price target on the stock. Finally, William Blair started coverage on shares of Evommune in a research note on Monday. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $39.33.

Evommune Stock Performance

Shares of EVMN opened at $21.54 on Monday. Evommune has a twelve month low of $16.70 and a twelve month high of $24.03.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.